Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Breast Cancer Research : Bcr
Miyashita, Minoru M; Bell, Joshua S K JSK; Wenric, Stephane S; Karaesmen, Ezgi E; Rhead, Brooke B; Kase, Matthew M; Kaneva, Kristiyana K; De La Vega, Francisco M FM; Zheng, Yonglan Y; Yoshimatsu, Toshio F TF; Khramtsova, Galina G; Liu, Fang F; Zhao, Fangyuan F; Howard, Frederick M FM; Nanda, Rita R; Beaubier, Nike N; White, Kevin P KP; Huo, Dezheng D; Olopade, Olufunmilayo I OI
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Nature Communications
Sivakumar, Smruthy S; Jin, Dexter X DX; Tukachinsky, Hanna H; Murugesan, Karthikeyan K; McGregor, Kimberly K; Danziger, Natalie N; Pavlick, Dean D; Gjoerup, Ole O; Ross, Jeffrey S JS; Harmon, Robert R; Chung, Jon J; Decker, Brennan B; Dennis, Lucas L; Frampton, Garrett M GM; Molinero, Luciana L; Oesterreich, Steffi S; Venstrom, Jeffrey M JM; Oxnard, Geoffrey R GR; Hegde, Priti S PS; Sokol, Ethan S ES
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
Npj Breast Cancer
Pancholi, Sunil S; Simigdala, Nikiana N; Ribas, Ricardo R; Schuster, Eugene E; Leal, Mariana Ferreira MF; Nikitorowicz-Buniak, Joanna J; Rega, Camilla C; Bihani, Teeru T; Patel, Hitisha H; Johnston, Stephen R SR; Dowsett, Mitch M; Martin, Lesley-Ann LA
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Research And Treatment
Bardia, Aditya A; Mayer, Ingrid I; Winer, Eric E; Linden, Hannah M HM; Ma, Cynthia X CX; Parker, Barbara A BA; Bellet, Meritxell M; Arteaga, Carlos L CL; Cheeti, Sravanthi S; Gates, Mary M; Chang, Ching-Wei CW; Fredrickson, Jill J; Spoerke, Jill M JM; Moore, Heather M HM; Giltnane, Jennifer J; Friedman, Lori S LS; Chow Maneval, Edna E; Chan, Iris I; Jhaveri, Komal K
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Oncogene
Harrod, Alison A; Lai, Chun-Fui CF; Goldsbrough, Isabella I; Simmons, Georgia M GM; Oppermans, Natasha N; Santos, Daniela B DB; Győrffy, Balazs B; Allsopp, Rebecca C RC; Toghill, Bradley J BJ; Balachandran, Kirsty K; Lawson, Mandy M; Morrow, Christopher J CJ; Surakala, Manasa M; Carnevalli, Larissa S LS; Zhang, Pei P; Guttery, David S DS; Shaw, Jacqueline A JA; Coombes, R Charles RC; Buluwela, Lakjaya L; Ali, Simak S
Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
British Journal Of Cancer
Fernandez-Garcia, Daniel D; Nteliopoulos, Georgios G; Hastings, Robert K RK; Rushton, Amelia A; Page, Karen K; Allsopp, Rebecca C RC; Ambasager, Bana B; Gleason, Kelly K; Guttery, David S DS; Ali, Simak S; Charles Coombes, R R; Shaw, Jacqueline A JA
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Molecular Cancer
Mo, Hongnan H; Liu, Xuefeng X; Xue, Yu Y; Chen, Hongyan H; Guo, Shichao S; Li, Zhangfu Z; Wang, Shuang S; Li, Caiming C; Han, Jiashu J; Fu, Ming M; Song, Yongmei Y; Li, Dan D; Ma, Fei F
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Nature Communications
Bardia, Aditya A; Chandarlapaty, Sarat S; Linden, Hannah M HM; Ulaner, Gary A GA; Gosselin, Alice A; Cartot-Cotton, Sylvaine S; Cohen, Patrick P; Doroumian, Séverine S; Paux, Gautier G; Celanovic, Marina M; Pelekanou, Vasiliki V; Ming, Jeffrey E JE; Ternès, Nils N; Bouaboula, Monsif M; Lee, Joon Sang JS; Bauchet, Anne-Laure AL; Campone, Mario M
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Nature Communications
Li, Zheqi Z; McGinn, Olivia O; Wu, Yang Y; Bahreini, Amir A; Priedigkeit, Nolan M NM; Ding, Kai K; Onkar, Sayali S; Lampenfeld, Caleb C; Sartorius, Carol A CA; Miller, Lori L; Rosenzweig, Margaret M; Cohen, Ofir O; Wagle, Nikhil N; Richer, Jennifer K JK; Muller, William J WJ; Buluwela, Laki L; Ali, Simak S; Bruno, Tullia C TC; Vignali, Dario A A DAA; Fang, Yusi Y; Zhu, Li L; Tseng, George C GC; Gertz, Jason J; Atkinson, Jennifer M JM; Lee, Adrian V AV; Oesterreich, Steffi S
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.
Annals Of Translational Medicine
Shim, Hyoeun H; Kwon, Min Jeong MJ; Park, In Hae IH; Kim, Min Kyeong MK; Cho, Eun-Hae EH; Lee, Junnam J; Lee, Seung-Tae ST; Sim, Sung Hoon SH; Lee, Keun Seok KS; Kim, Yun-Hee YH; Kim, Seok-Ki SK; Lee, Eun Sook ES; Kong, Sun-Young SY
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Nature Cancer
Guillen, Katrin P KP; Fujita, Maihi M; Butterfield, Andrew J AJ; Scherer, Sandra D SD; Bailey, Matthew H MH; Chu, Zhengtao Z; DeRose, Yoko S YS; Zhao, Ling L; Cortes-Sanchez, Emilio E; Yang, Chieh-Hsiang CH; Toner, Jennifer J; Wang, Guoying G; Qiao, Yi Y; Huang, Xiaomeng X; Greenland, Jeffery A JA; Vahrenkamp, Jeffery M JM; Lum, David H DH; Factor, Rachel E RE; Nelson, Edward W EW; Matsen, Cindy B CB; Poretta, Jane M JM; Rosenthal, Regina R; Beck, Anna C AC; Buys, Saundra S SS; Vaklavas, Christos C; Ward, John H JH; Jensen, Randy L RL; Jones, Kevin B KB; Li, Zheqi Z; Oesterreich, Steffi S; Dobrolecki, Lacey E LE; Pathi, Satya S SS; Woo, Xing Yi XY; Berrett, Kristofer C KC; Wadsworth, Mark E ME; Chuang, Jeffrey H JH; Lewis, Michael T MT; Marth, Gabor T GT; Gertz, Jason J; Varley, Katherine E KE; Welm, Bryan E BE; Welm, Alana L AL
Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
Oncogene
Mota, Alba A; Oltra, Sara S SS; Selenica, Pier P; Moiola, Cristian P CP; Casas-Arozamena, Carlos C; López-Gil, Carlos C; Diaz, Eva E; Gatius, Sonia S; Ruiz-Miro, María M; Calvo, Ana A; Rojo-Sebastián, Alejandro A; Hurtado, Pablo P; Piñeiro, Roberto R; Colas, Eva E; Gil-Moreno, Antonio A; Reis-Filho, Jorge S JS; Muinelo-Romay, Laura L; Abal, Miguel M; Matias-Guiu, Xavier X; Weigelt, Britta B; Moreno-Bueno, Gema G
Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
Jco Precision Oncology
Page, Karen K; Martinson, Luke J LJ; Fernandez-Garcia, Daniel D; Hills, Allison A; Gleason, Kelly L T KLT; Gray, Molly C MC; Rushton, Amelia J AJ; Nteliopoulos, Georgios G; Hastings, Robert K RK; Goddard, Kate K; Ions, Charlotte C; Parmar, Vilas V; Primrose, Lindsay L; Openshaw, Mark R MR; Guttery, David S DS; Palmieri, Carlo C; Ali, Simak S; Stebbing, Justin J; Coombes, R Charles RC; Shaw, Jacqueline A JA
Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies.
Cancers
Al-Qasem, Abeer J AJ; Alves, Carla L CL; Ditzel, Henrik J HJ
An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Breast Cancer Research : Bcr
Scherer, Sandra D SD; Riggio, Alessandra I AI; Haroun, Fadi F; DeRose, Yoko S YS; Ekiz, H Atakan HA; Fujita, Maihi M; Toner, Jennifer J; Zhao, Ling L; Li, Zheqi Z; Oesterreich, Steffi S; Samatar, Ahmed A AA; Welm, Alana L AL
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Cancer Research
Gou, Xuxu X; Anurag, Meenakshi M; Lei, Jonathan T JT; Kim, Beom-Jun BJ; Singh, Purba P; Seker, Sinem S; Fandino, Diana D; Han, Airi A; Rehman, Saif S; Hu, Jianhong J; Korchina, Viktoriya V; Doddapaneni, Harshavardhan H; Dobrolecki, Lacey E LE; Mitsiades, Nicholas N; Lewis, Michael T MT; Welm, Alana L AL; Li, Shunqiang S; Lee, Adrian V AV; Robinson, Dan R DR; Foulds, Charles E CE; Ellis, Matthew J MJ
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Npj Breast Cancer
Gombos, Andrea A; Venet, David D; Ameye, Lieveke L; Vuylsteke, Peter P; Neven, Patrick P; Richard, Vincent V; Duhoux, Francois P FP; Laes, Jean-Francois JF; Rothe, Françoise F; Sotiriou, Christos C; Paesmans, Marianne M; Awada, Ahmad A; Guiot, Thomas T; Flamen, Patrick P; Piccart-Gebhart, Martine M; Ignatiadis, Michail M; Gebhart, Géraldine G